Andere Sprachen Ionis Pharmaceuticals, Inc.

Aktien

A2ACMZ

US4622221004

IONS

Realtime-Estimate Cboe BZX Andere Börsenplätze 19:37:04 29.04.2024			% 5 Tage	% 1. Jan.
42,2 ^USD	+1,45 %		+2,87 %	-16,49 %

10.04.	IONIS PHARMACEUTICALS, INC. : Von Wolfe Research zum Kauf angehoben	ZM
09.04.	IONIS PHARMACEUTICALS, INC. : Bewertung von Oppenheimer zum Kaufen erhalten	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ionis Publishes 2023 Corporate Responsibility Report	25.04.
Ionis to hold first quarter 2024 financial results webcast	23.04.
North American Morning Briefing : Stock Futures -2-	11.04.
North American Morning Briefing : Traders Await -2-	10.04.
Ionis Pharmaceuticals : Listen to webcast	09.04.
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome	08.04.
Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome	07.04.
Ionis to present at upcoming investor conferences	01.04.
Ionis Pharmaceuticals - Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology annual meeting	26.03.
Sector Update: Health Care Stocks Gain Premarket Wednesday	13.03.
Ionis Pharmaceuticals' Phase 2 Study of ION224 Achieves Liver Histologic Improvement; Shares Up	13.03.
Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial	13.03.
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH	13.03.
Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224	13.03.
Ionis Pharmaceuticals, Inc. Announces Executive Changes	29.02.
Ionis announces new chief global product strategy officer to lead next phase of commercial growth	29.02.
Ionis to present at upcoming investor conferences	28.02.
Travere drug for rare kidney condition recommended for EU approval	23.02.
Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday	21.02.
Ionis Pharmaceuticals' Q4 Net Loss Narrows as Revenue Increases; Provides 2024 Revenue Guidance; Shares Gain Pre-Bell	21.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ionis Pharmaceuticals, Inc.

Aktien

A2ACMZ

US4622221004

IONS

Andere Sprachen

Filter